Development and Validation of a Real-time Prediction Model for Acute Kidney Injury in Hospitalized Patients

NCT ID: NCT06597838

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

161876 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-28

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Early prediction of acute kidney injury (AKI) may provide a crucial opportunity for AKI prevention. To date, no prediction model targeting AKI among general hospitalized patients in developing countries has been published. We developed a simple, real-time, interpretable AKI prediction model for general hospitalized patients from a large tertiary hospital in China, and validated it across five independent, geographically distinct, different tiered hospitals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Early prediction of acute kidney injury (AKI) may provide a crucial opportunity for AKI prevention. To date, no prediction model targeting AKI among general hospitalized patients in developing countries has been published. We developed a simple, real-time, interpretable AKI prediction model for general hospitalized patients from a large tertiary hospital in China using the machine learning technique, and then validated the performance of the prediction model across five independent, geographically distinct, different tiered hospitals in China.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prediction Model

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (18 years and older) admitted to five hospitals during the study period

Exclusion Criteria

* Have less than 2 documented serum creatinine (Scr) measurements during hospitalization
* Being diagnosed with end-stage renal disease (ESRD)
* Maintained on dialysis or had an initial Scr greater than or equal to 4.0 mg/dL at admission
* Developed AKI prior to admission or within 24 hours after admission
* Length of stay shorter than 24 hours
* Underwent kidney transplantation or nephrectomy during hospitalization
* With all Scr measurements lower than or equal to 0.6 mg/dL from 90 days prior to admission until discharge.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University First Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Li Yang

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Li Yang

Role: STUDY_DIRECTOR

Peking University First Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University First Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuhui Zhang

Role: CONTACT

+86 18813037026

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yuhui Zhang

Role: primary

+86 18813037026

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023[069-001]

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Risk Factors and Deep Learning Model for CI-AKI
NCT06596785 ACTIVE_NOT_RECRUITING
Preventing Acute Kidney Injury
NCT04376619 WITHDRAWN NA